Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.


BACKGROUND Our previous studies have shown that the in vitro cytotoxicity of gemcitabine and SN-38, the active metabolite of irinotecan (CPT-11), is synergistic in human tumor cell lines. PATIENTS AND METHODS Twenty-four patients with solid tumors, refractory to standard chemotherapy or for whom no effective therapy existed (age range 31-74; 7 female, 17… (More)


3 Figures and Tables

Slides referencing similar topics